← Back to Clinical Trials
Recruiting NCT06194357

NCT06194357 Integrated Mindfulness-based Health Qigong Intervention for COVID-19 Survivors and Caregivers

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06194357
Status Recruiting
Phase
Sponsor The Hong Kong Polytechnic University
Condition COVID-19 Infection
Study Type INTERVENTIONAL
Enrollment 600 participants
Start Date 2023-01-30
Primary Completion 2026-09-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Mindfulness-based Health Qigong Intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 600 participants in total. It began in 2023-01-30 with a primary completion date of 2026-09-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

COVID-19-related depression, anxiety, and stigma are expected to have short-term and long-term adverse impacts on mental health, help seeking and preventive behaviours in affected individuals, including care providers and the general population. Health qigong (HQ), a form of traditional Chinese martial arts with emphasis placed on the body movement and status of mind, has been demonstrated to enhance both physical and mental health. Mindfulness-based interventions (MBIs), another mind-body treatment, have become increasingly popular for treating a number of health problems. This study proposes an integrated intervention that combines the effects of HQ and MBIs (iMBHQ) to improve the mental wellbeing of COVID-19 survivors, caregivers including healthcare providers and family members as well as the general public in the community.

Eligibility Criteria

Inclusion Criteria: * COVID-19 survivors: people aged 18 years or above who were infected by COVID-19 (both symptomatic and asymptomatic) and clinically recovered * Caregivers of COVID-19 patients, including family members or medical professionals who have contacts with patients diagnosed COVID-19 aged 18 years or above * General healthy public aged 18 years or above Exclusion Criteria: * people diagnosed severe and/or chronic conditions that prevent the practice of Qigong (e.g., acute exacerbation of dyspnoea, severe cardiopulmonary disease) or mindfulness intervention, * people with severe psychiatric disorder * people who have regular psychiatric follow-ups

Contact & Investigator

Central Contact

Travis,Tsz-kwun Law, Mr

✉ tk120@ha.org.hk

📞 29901017

Principal Investigator

Wing Hong, Hector TSANG, Prof

PRINCIPAL INVESTIGATOR

Department of Rehabilitation Science, Faculty of Health and Social Sciences

Frequently Asked Questions

Who can join the NCT06194357 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying COVID-19 Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06194357 currently recruiting?

Yes, NCT06194357 is actively recruiting participants. Contact the research team at tk120@ha.org.hk for enrollment information.

Where is the NCT06194357 trial being conducted?

This trial is being conducted at Hong Kong, Hong Kong.

Who is sponsoring the NCT06194357 clinical trial?

NCT06194357 is sponsored by The Hong Kong Polytechnic University. The principal investigator is Wing Hong, Hector TSANG, Prof at Department of Rehabilitation Science, Faculty of Health and Social Sciences. The trial plans to enroll 600 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology